Tevogen Bio Holdings Inc. (TVGN) 8-K Current Report: February 25, 2026
Filed: February 25, 2026
Health Care
Biological Products, (No Diagnostic Substances)Tevogen Bio Holdings Inc. (TVGN) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 5.07: Submission of Matters to a Vote of Security Holders
Tevogen Bio Holdings Inc. 8-K Feb 25, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Special Meeting held Feb 19, 2026 — filing appears truncated, full officer change details not captured in provided text
- • Item 5.02 signals a material leadership change (departure, appointment, or compensation update) — full exhibit review required for specifics
Item 5.07 · Submission of Matters to a Vote of Security Holders
- • Reverse split ratio approved: 1:25 to 1:85, exact ratio and timing at Board's sole discretion — significant dilution risk reduction but share count compression pending
- • Reverse split passed with 176.3M votes for vs. 6.0M against (~96.7% approval) out of 182.4M shares present
- • Equity plan amendment (2024 Plan Amendment) also approved: 147.8M for vs. 4.7M against — expands share-based compensation capacity
- • Record date shares outstanding: 201.5M — post-split share count could range from ~2.4M (1:85) to ~8.1M (1:25) depending on Board decision
- • Board retains full discretion on timing and exact ratio; split not yet enacted — watch for follow-on 8-K triggering actual execution
Other Tevogen Bio Holdings Inc. 8-K Filings
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.